BLAC — Bellevue Life Sciences Acquisition Share Price
Last trade - 00:00- $43.65m
- $43.78m
- 27
- 32
- 36
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.34 | ||
| Price to Tang. Book | 1.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.8% | ||
| Return on Equity | 0.46% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bellevue Life Sciences Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company has not selected any business combination target, and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company may pursue an acquisition opportunity in any business industry or sector. The Company intends to acquire and manage a business in the healthcare industry, more specifically in the biotechnology sector. The Company neither engaged in any operations nor generated any revenues.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 25th, 2020
- Public Since
- February 10th, 2023
- No. of Shareholders
- 8
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 4,041,221
- Address
- 10900 Ne 4Th Street, Suite 2300, BELLEVUE, 98004
- Web
- Phone
- +1 4256357700
- Auditors
- WithumSmith Brown PC
Similar to BLAC
1Sharpe Acquisition
NASDAQ Capital Market
5G Edge Acquisition
NASDAQ Capital Market
Able Brands Co
NASDAQ Capital Market
Acamar Partners Acquisition II
NASDAQ Capital Market
Acies Acquisition II
NASDAQ Capital Market
FAQ
As of Today at 19:35 UTC, shares in Bellevue Life Sciences Acquisition are trading at $10.75. This share price information is delayed by 15 minutes.
Shares in Bellevue Life Sciences Acquisition last closed at $10.75 and the price had moved by +5.29% over the past 365 days. In terms of relative price strength the Bellevue Life Sciences Acquisition share price has underperformed the S&P500 Index by -16.22% over the past year.
There is no consensus recommendation for this security.
Bellevue Life Sciences Acquisition does not currently pay a dividend.
Bellevue Life Sciences Acquisition does not currently pay a dividend.
Bellevue Life Sciences Acquisition does not currently pay a dividend.
To buy shares in Bellevue Life Sciences Acquisition you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $10.75, shares in Bellevue Life Sciences Acquisition had a market capitalisation of $43.44m.
Here are the trading details for Bellevue Life Sciences Acquisition:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BLAC
Based on an overall assessment of its quality, value and momentum Bellevue Life Sciences Acquisition is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bellevue Life Sciences Acquisition. Over the past six months, its share price has underperformed the S&P500 Index by -10.29%.
As of the last closing price of $10.75, shares in Bellevue Life Sciences Acquisition were trading +3.1% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bellevue Life Sciences Acquisition PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Bellevue Life Sciences Acquisition's directors